erenumab Aimovig
Selected indexed studies
- In brief: Erenumab (Aimovig) hypersensitivity. (Med Lett Drugs Ther, 2019) [PMID:31022159]
- Erenumab. (, 2006) [PMID:30000991]
- Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. (Cephalalgia, 2022) [PMID:34743579]
_Worker-drafted node — pending editorial review._
Connections
erenumab Aimovig is a side effect of
Sources
- Erenumab. (2006) pubmed
- A Controlled Trial of Erenumab for Episodic Migraine. (2017) pubmed
- Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. (2022) pubmed
- Erenumab. (2012) pubmed
- Erenumab: First Global Approval. (2018) pubmed
- Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial. (2024) pubmed
- In brief: Erenumab (Aimovig) hypersensitivity. (2019) pubmed
- Erenumab (Aimovig) for migraine prevention. (2018) pubmed
- Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors. (2024) pubmed
- PMID:33476110 (2020) pubmed